Yves Sabbagh, Ph.D., is our senior vice president and chief scientific officer, joining Inozyme in October 2020. Dr. Sabbagh brings to Inozyme more than 25 years of experience in rare genetic disorders and mineral metabolism with responsibilities leading to the identification and evaluation of novel therapeutic approaches and translating them into clinical candidates through IND.
Prior to joining Inozyme, Dr. Sabbagh served as global head of rare renal and musculoskeletal diseases research at Sanofi’s rare disease and neurological unit, advancing a pipeline of drug candidates using multiple therapeutic modalities, including proteins and small molecules. Prior to that executive role, he held scientific roles of increasing responsibility at Sanofi and Genzyme Corporation spanning endocrine, renal and rare bone diseases including driving the strategy for rare bone indications such as osteogenesis imperfecta and achondroplasia and managing research in disease mechanisms, and target discovery/validation. Prior to his corporate experience, he was an instructor at the Harvard Medical School in the Endocrine unit. Dr. Sabbagh has co-authored more than 40 peer-reviewed publications and book chapters and is a member of several scientific societies. Dr. Sabbagh has won various awards for his work throughout his career. Dr. Sabbagh received a B.Sc. in biochemistry from McGill University, an MSc in microbiology from Université Laval and a Ph.D. in biology from McGill University and performed post-doctoral research at Harvard Medical School in the Endocrine Unit at Massachusetts General Hospital.
